CellaVision AB

Equities

CEVI

SE0000683484

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm Other stock markets 11:29:51 2024-05-22 EDT			5-day change	1st Jan Change
266 ^SEK	+0.57%		+15.15%	+25.47%

04-25	Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024
04-25	CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cellavision AB Announces Appointment of Magnus Blixt as Acting CEO

October 23, 2020 at 05:00 am

CellaVision AB announced appointment of Magnus Blixt as acting CEO that will step in when Zlatko Rihter leave. Magnus Blixt, who has been the CFO for the last 7 years at the company. Zlatko Rihter will leave end of November.

Latest news about CellaVision AB

Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024	04-25
CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Transcript : CellaVision AB, Q4 2023 Earnings Call, Feb 07, 2024	02-07
CellaVision AB Proposes Dividend for the Year 2023	02-07	CI
CellaVision AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-07	CI
Cellavision, Sysmex Expand Hematology Partnership Deal	02-06	MT
CellaVision and Sysmex Corporation Sign Strategic Alliance Agreement	02-06	CI
Transcript : CellaVision AB, Q3 2023 Earnings Call, Oct 25, 2023	23-10-25
CellaVision AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-25	CI
Transcript : CellaVision AB, Q2 2023 Earnings Call, Jul 20, 2023	23-07-20
CellaVision AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-20	CI
Cellavision AB Announces Executive Changes	23-05-05	CI
Cellavision AB Approves Dividend, Payable on May 12, 2023	23-05-05	CI
Transcript : CellaVision AB, Q1 2023 Earnings Call, May 04, 2023	23-05-04
CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
CellaVision AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-08	CI
Transcript : CellaVision AB, Q4 2022 Earnings Call, Feb 07, 2023	23-02-07
CellaVision AB Proposes Dividend for 2022, Payable on 12 May 2023	23-02-07	CI
CellaVision AB Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee	22-11-25	CI
Transcript : CellaVision AB, Q3 2022 Earnings Call, Oct 26, 2022	22-10-26
CellaVision AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology Laboratories	22-07-27	CI
Transcript : CellaVision AB, Q2 2022 Earnings Call, Jul 20, 2022	22-07-20
CellaVision AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-20	CI
CellaVision AB Appoints Ann-Charlotte Jarleryd as Board Member	22-05-11	CI

Chart CellaVision AB

Duration

Period

More charts

Company Profile

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-19 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for CellaVision AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

266 SEK

Average target price

257.5 SEK

Spread / Average Target

-3.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
CELLAVISION AB	+25.47%	591M
SARTORIUS AG	-20.71%	17.75B
QUIDELORTHO CORPORATION	-42.20%	2.85B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+21.31%	1.92B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-5.07%	1.58B
BIOTAGE AB	+34.03%	1.34B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-17.46%	952M
CONTEC MEDICAL SYSTEMS CO.,LTD	-22.39%	888M
REVENIO GROUP OYJ	+5.74%	828M
VAREX IMAGING CORPORATION	-27.07%	611M

Medical Diagnostic & Testing Equipment